Psyence BioMed Invested in PsyLabs for Texas Trial
The firm committed $5 million and initiated a share exchange to support clinical trials for pharmaceutical-grade ibogaine.
Updated on Sept. 23, 2026 in Healthcare
Live Poll
Should pharmaceutical companies prioritize the development and manufacturing of experimental drugs for clinical research?
Psyence BioMed has committed $5 million to PsyLabs and finalized a value-matched share exchange worth $9 million per side. The partnership aims to accelerate the manufacturing of pharmaceutical-grade ibogaine ahead of a planned clinical trial in Texas.
Why it matters
This investment aligns the operational capabilities of both firms to advance the development and testing of ibogaine for medical use. The collaboration is centered on establishing a regulatory framework for an upcoming U.S. clinical trial.
Psyence BioMed committed an initial $2.4 million cash payment as part of a $5 million total investment plan. The deal includes a share exchange involving approximately $9 million in transaction value on each side.
The players
Psyence BioMed
This is a biotechnology company focused on the development and production of psilocybin and ibogaine for medicinal use.
PsyLabs
PsyLabs is a biotechnology firm specializing in the development of psychedelic compounds for psychiatric and clinical research.
Texas Ibogaine Research Corporation
This is a newly established subsidiary of Psyence BioMed formed to facilitate clinical research operations within Texas.
The details
The transaction includes the issuance of 1,497,500 Psyence BioMed common shares and 3,473 PsyLabs ordinary shares. Psyence BioMed has established a subsidiary, Texas Ibogaine Research Corporation, to oversee the planned medical research activities in the state.
Timeline
September 23, 2026: The investment and share exchange agreement was announced.
November 30, 2026: The deadline for completion of the share exchange agreement.
December 31, 2026: The deadline for completing the investment milestone tranches.
Market Landscape
This integration of manufacturing and research assets reflects the broader industry trend of consolidating specialized supply chains for controlled substances. The partnership positions the firms to compete in the growing market for psychiatric drug development.
The investment focuses on the long-term development of clinical trials, meaning there are no immediate changes to existing healthcare services for the public. Residents may follow the progress of the planned Texas clinical trial as the firms meet their research milestones.
The takeaway
This deal underscores the capital-intensive nature of bringing psychedelic-based treatments through clinical trials. Investors and patients should monitor the upcoming milestones to gauge the timeline for potential future therapeutic availability.
What happens next
The share exchange agreement must conclude by November 30, 2026, while the remaining $2.6 million investment tranches are subject to milestone deadlines ending December 31, 2026.
Further reading
For additional updates on medical research developments, visit the Healthcare section.
Live Poll
Should pharmaceutical companies prioritize the development and manufacturing of experimental drugs for clinical research?
